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Erythropoietic protoporphyria (EPP) is caused by a defect in ferrochelatase, leading to the accumulation of
protoporphyrin predominantly in erythrocytes and hepatocytes, and resulting in skin photosensitivity upon
leaching of blood protoporphyrin into the skin. Some patients also develop severe liver damage. Because the
respective contributions of hepatic and erythrocytic protoporphyrin to the pathophysiology of EPP remain unclear,
we investigated this question using the murine model of EPP. Transplantation of bone marrow from EPP mice to
normal recipients resulted in elevated erythrocyte and plasma protoporphyrin levels. However, quantiﬁcation of
serum liver enzymes and bilirubin together with histopathologic examination of liver sections of mice up to 16
months post-transplantation showed no evidence of liver damage. Moreover, despite massive elevation of serum
protoporphyrin, transplanted mice showed minimal evidence of skin photosensitivity. Photosensitivity could also
be prevented locally by implanting skin grafts from normal mice onto the backs of EPP recipients. These data
validate the hypothesis that the main source of toxic protoporphyrin originates from the erythrocytes. However, we
unexpectedly observed that normal ferrochelatase activity in hepatic and dermal cells of wild-type mice is sufﬁcient
to prevent liver disease and signiﬁcant skin photosensitivity. These ﬁndings may provide new strategies for the
treatment of EPP.
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Erythropoietic protoporphyria (EPP) is a hereditary disorder
of porphyrin metabolism in which the activity of fe-
rrochelatase, the enzyme responsible for inserting iron into
protoporphyrin to form heme, is reduced (Desnick, 1994).
Although ferrochelatase is produced in all tissues of the
body, this decrease in ferrochelatase activity (15%–40% of
normal) leads to the accumulation of large amounts of
protoporphyrin in erythrocytes because of the fact that
porphyrin metabolism is especially active in these cells
(Desnick, 1994). The accumulated protoporphyrin leaks into
the plasma, ultimately producing the clinical symptom that
is the hallmark of this disease: severe photosensitivity of
light-exposed skin resulting in itching, burning, and rarely
ulceration (Desnick, 1994). Moreover, approximately 5% of
EPP patients are at risk for developing cholestasis from the
abnormal accumulation of excess protoporphyrin in he-
patocytes, causing progressive liver damage and eventual
liver failure (Bloomer, 1999). Other rare systemic symptoms
include hemolytic anemia and peripheral neuropathy (Key
et al, 1992).
Currently, treatment for EPP consists of preventing or
lessening photosensitization by ingesting b-carotene. This
treatment is, however, ineffective in approximately 20% of
patients (Mathews-Roth et al, 1977) and does not protect
against liver damage. Alternatively, bone marrow transplan-
tation has the potential to reduce or eliminate erythrocytic
protoporphyrin (Poh-Fitzpatrick et al, 2002), although the
feasibility of this approach is limited by the requirement for a
human leukocyte antigen-matched donor. Autologous
transplantation of genetically modified bone marrow re-
mains an attractive alternative in the absence of a suitable
donor. Bone marrow transplantation with either allogeneic
cells or autologous, genetically modified cells would,
however, not protect the patient from cirrhosis and even-
tual liver failure, if hepatic-derived protoporphyrin plays a
significant role in the development of liver damage. The role
of hepatic protoporphyrin production in the development
of liver damage remains unclear (Bloomer, 1999). A detailed
understanding of how hepatic and erythrocytic-derived
protoporphyrin contribute to photosensitivity and liver
disease is critical to the development of strategies aimed
at treating EPP.
A mouse model of EPP, BALB/C-Fechm1Pas, is charac-
terized by a profound deficiency in ferrochelatase enzyme
activity (less than 6% of normal control mice) caused by a
Abbreviations: EPP, erythropoietic protoporphyria; HSC, hem-
atopoietic stem cell
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missense mutation in the ferrochelatase gene (Tutois et al,
1991; Boulechfar et al, 1993). These mice demonstrate high
levels of protoporphyrin in erythrocytes, plasma, liver, and
stool and, importantly, show all the clinical features ob-
served in human EPP patients including hemolytic anemia,
photosensitivity, cholestasis, and severe liver dysfunction
(Tutois et al, 1991; Boulechfar et al, 1993). In contrast to
human patients, all BALB/C-Fechm1Pas mice develop irre-
versible liver damage (Tutois et al, 1991). We have previ-
ously utilized this mouse model to demonstrate long-term
cure of photosensitivity by retrovirus-mediated, preselective
hematopoietic stem cell (HSC) gene therapy (Pawliuk et al,
1999). More recently, other groups have confirmed our
findings and demonstrated either complete or partial cor-
rection of photosensitivity in EPP mice with or without pre-
selection of transduced cells (Fontanellas et al, 2001;
Richard et al, 2001).
Using BALB/C-Fechm1Pas mice as a model of human
EPP, we sought to define, more precisely, the relative con-
tributions of hepatic and erythrocytic protoporphyrin to the
development of EPP-associated photosensitivity and liver
disease. Transplantation of bone marrow from BALB/C-
Fechm1Pas mice into congenic BALB/C recipients confirmed
that the vast majority of protoporphyrin derives from the red
blood cell compartment and demonstrated that in the pres-
ence of normal cellular levels of hepatic and dermal fe-
rrochelatase, elevated plasma protoporphyrin levels alone
are insufficient to generate EPP-associated liver disease
and significant photosensitivity.
Results
Elevation of erythrocytic protoporphyrin concentration
and the percentage of protoporphyrin ﬂuorescent red
blood cells in normal BALB/C recipients of EPP donor
marrow Femoral bone marrow was isolated from female
EPP donors and 7.2  106 cells were injected intravenously
into irradiated male BALB/C recipient mice. As a control,
bone marrow was also harvested from normal female
BALB/C donors and 8.3  106 cells were transplanted into
irradiated male BALB/C recipients. A total of five and four
recipients were transplanted with EPP and BALB/C donor
marrow, respectively. Mice were kept for long-term studies
and monitored at regular intervals by biochemical and flu-
orescent activated cell sorting (FACS) analysis. At 3 mo
post-transplantation, intracellular protoporphyrin concen-
trations were greatly elevated in the red blood cells of
BALB/C mice transplanted with EPP marrow and were
indistinguishable from the non-transplanted EPP control
mouse (Fig 1A). As expected, the concentration of pro-
toporphyrin in red blood cells from BALB/C mice trans-
planted with normal BALB/C marrow was not elevated and
was essentially identical to a non-transplanted BALB/C
control mouse (Fig 1A). These levels remained relatively
constant for at least 16 mo post-transplantation, the longest
time point assessed.
Next, to investigate the reconstitution of the erythroid
compartment with red blood cells derived from the abnor-
mal EPP donor bone marrow, we analyzed circulating red
blood cells from recipient mice by FACS. Protoporphyrin
was excited at 488 nm whereas a 650 nm filter was used to
detect protoporphyrin-specific fluorescence at 3 mo post-
transplantation. Flow cytometric analysis of circulating red
blood cells from normal BALB/C recipients transplanted
with EPP marrow showed that the proportion of pro-
toporphyrin fluorescent red blood cells was comparable
with that observed in unmanipulated EPP disease mice
(38%  2.2% (standard deviation (SD)) vs 51.5%  3.3%
(SD); p40.1) and greatly elevated as compared with
Figure1
Concentration of erythrocytic protoporphyrin (A) and percentage
of protoporphyrin fluorescent red blood cells (B) 3 mo post-trans-
plantation. BALB/C recipient mice were transplanted with either dis-
ease erythropoietic protoporphyria (EPP) marrow (EPP-BALB/C) (five
mice) or normal marrow (BALB/C–BALB/C) (three mice). Two non-
transplanted (Non-Tx) BALB/C and two EPP mice were used as controls.
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recipients of normal BALB/C donor marrow (38%  2.2%
(SD) vs 3.9%  1.6% (SD); po0.001) (Figs 1B and 2).
These data demonstrate high level engraftment of BALB/
C recipient mice with transplanted donor EPP bone marrow
leading to the production of circulating red blood cells with
a greatly elevated intracellular and plasma protoporphyrin
levels.
Absence of liver damage in normal BALB/C mice trans-
planted with EPP donor marrow EPP model mice are
characterized by severe hepatic dysfunction including bili-
ary cirrhosis, regenerative hyperplasia, extracellular depo-
sition of protoporphyrin, and a marked elevation in serum
concentrations of bilirubin, alkaline phosphatase, aspartate
amino-transaminase (AST), and alanine amino-transferase
(ALT) (Boulechfar et al, 1993). To investigate whether the
elevated levels of protoporphyrin in the plasma of normal
BALB/C recipients of EPP disease marrow was sufficient to
generate liver damage, serum levels of bilirubin, alkaline
phosphatase, AST, and ALT were monitored at regular in-
tervals. As shown in Table I, the concentration of liver en-
zymes and bilirubin in serum collected from BALB/C
recipients transplanted with EPP marrow were comparable
with non-transplanted control BALB/C mice and BALB/C
mice transplanted with normal BALB/C marrow. As expect-
ed, non-transplanted control disease EPP mice showed
markedly elevated levels of bilirubin and liver enzymes in the
serum. Moreover, histologic examination of hematoxylin
and eosin-stained liver sections taken from representative
recipients of BALB/C or EPP donor marrow sacrificed 3 mo
after transplantation showed no evidence of biliary cirrhosis,
regenerative hyperplasia, or extracellular deposits of pro-
toporphyrin in BALB/C recipients of either normal BALB/C
or EPP donor marrow (Fig 3). In contrast, examination of
liver sections of non-transplanted EPP control mice showed
extensive areas of biliary cirrhosis, regenerative hyperpl-
asia, and extracellular protoporphyrin deposits as previous-
ly described for this mouse model (Tutois et al, 1991). These
results were consistent out to 16 mo after transplant, the
longest time point tested. Together, these data demonstrate
that the extremely high levels of blood protoporphyrin gen-
erated following transplantation of BALB/C mice with EPP
bone marrow is insufficient to generate the severe liver
damage observed in the EPP mouse model.
BALB/C recipients of EPP marrow show minimal skin
photosensitivity despite high levels of plasma and
erythrocyte protoporphyrin Skin photosensitivity, the clini-
cal hallmark of EPP in humans, occurs as a result of
excitation of the circulating protoporphyrin molecule by
400–410 nm light near the surface of the skin. The excited
protoporphyrin reacts with molecular oxygen to produce a
reactive oxygen species that causes damage to cell mem-
branes and mitochondria. To investigate whether greatly el-
evated levels of plasma and erythrocyte protoporphyrin
levels were sufficient to generate the photosensitive phe-
notype, transplanted and control mice were taken at 3 mo
post-transplantation and shaved, depilated, and exposed to
20 min of a mercury vapor lamp that mimics exposure to
Figure 2
Fluorescent activated cell sorting analysis of red blood cells for
protoporphyrin specific fluorescence 3 mo post-transplantation.
Non-transplanted (Non-Tx) BALB/C and erythropoietic protoporphyria
(EPP) mice were used as controls. The percentage of protoporphyrin
fluorescent red blood cells is shown. BM, bone marrow.
Table I. Assessment of liver function
Transplanted mice
(number of mice)
Total bilirubin
(mg per dL)
Direct bilirubin
(mg per dL)
Indirect bilirubin
(mg per dL)
Alkaline
phosphatase
(U per liter)
ALT
(U per liter)
AST
(U per liter)
Non-Tx BALB/C (2) 0.22  0.01 0.01  0 0.23  0.01 111  4.9 35  4.2 49  2.8
Non-Tx EPP (2) 0.6  0.03 0.34  0.04 0.25  0.01 2109  107 754  47 838  15
BALB/C Tx with BALB/C (3)a 0.3  0.05 0.01  0.01 0.29  0.04 159  33 41  12.5 80  24.8
BALB/C Tx with EPP (4)a 0.23  0.03 0.01  0.01 0.22  0.03 141  3.7 36  1.9 53  3.9
aOne mouse from each group was sacrificed 3 mo after transplantation for liver histology and were not available for liver function analysis 12 mo after
transplantation.
ALT, alanine amino-transferase; AST, aspartate amino-transaminase; Tx, transplanted; EPP, erythropoietic protoporphyria. Non-transplanted BALB/C
and EPP mice were age matched with transplanted recipients.
Mice were analyzed 12 mo after transplantation. Data represent mean  standard deviation.
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sunlight. As expected, normal BALB/C mice showed no
evidence of burns or lesions on their backs whereas non-
transplanted control EPP disease mice showed severe
photosensitivity (Fig 4A and B). Surprisingly, those BALB/C
recipients of EPP donor marrow showed only minimal ev-
idence of photosensitivity despite having extremely high
levels of protoporphryin in their erythrocytes and plasma
(Fig 4C and D). Similar results were observed out to 16 mo
post-transplantation, the longest time point tested. These
data suggest that the expression of normal levels of fe-
rrochelatase in the skin is sufficient to provide a significant
protection against photosensitivity despite the greatly ele-
vated levels of photoreactive protoporphyrin in the plasma.
Expression of normal levels of ferrochelatase in skin
protects against photosensitivity In order to conclusively
demonstrate that normal levels of ferrochelatase enzyme
produced by the skin can provide a significant photopro-
tective effect despite high levels of photoreactive pro-
toporphyrin in the blood, we performed skin transplants
between normal BALB/C mice and disease EPP mice. Cir-
cular skin grafts of approximately 1.0 cm in size were taken
from the lumbar region of the dorsum of BALB/C (n¼2) and
EPP disease (n¼2) mice with a scalpel blade, switched,
and sutured into place. One mouse from each of the BALB/
C and EPP background groups died approximately 3–4 d
post-surgery presumably because of the procedure. The
grafts on the surviving mice rapidly became vascularized
and showed no signs of necrosis or tissue damage. One-
week post-transplantation, the concentration of erythrocytic
protoporphyrin in each remaining mouse was determined.
As expected, the mouse of the normal BALB/C background
showed a low concentration of protoporphyrin (2296 nmol
per liter) whereas the mouse of the EPP disease back-
ground showed a greatly elevated protoporphyrin concen-
tration (13,671 nmol per liter). Next, in order to determine
conclusively that the ferrochelatase enzyme produced by
cells of the normal BALB/C skin graft is sufficient to provide
a photoprotective effect within the EPP background, the
two mice were exposed to a mercury vapor lamp (5.52 J per
cm2 of 400–410 nm light) 1 mo post-transplantation. As
shown in Fig 5B, although the EPP disease mouse showed
evidence of severe photosensitivity on most of its exposed
back, the region corresponding to the location of the normal
Figure 3
Lack of liver disease in BALB/C recipients of erythropoietic protoporphyria (EPP) marrow. One representative BALB/C recipient of BALB/C or
EPP marrow was sacrificed 3 mo post-transplantation and the livers processed for histopathology. Sections were stained with hematoxylin/eosin
and analyzed by a Board Certified Veterinary Pathologist. Sections analyzed at  20 magnification (left panels) show the presence of large
regenerative nodules (arrow) in the non-transplanted (Non-Tx) EPP mouse but not in livers of BALB/C recipients of either BALB/C or EPP marrow.
Tissue sections analyzed at  100 magnification (right panels) showed biliary cirrhosis, large vacuoles, and extracellular protoporphyrin deposits in
the liver of the non-transplanted EPP mouse whereas no abnormalities were observed in the livers of BALB/C recipients of either BALB/CV or EPP
marrow. BM, bone marrow.
AMELIORATION OF PHOTOSENSITIVITY AND LIVER DISEASE 259124 : 1 JANUARY 2005
BALB/C skin graft showed only minimal evidence of pho-
tosensitivity. As expected, since the levels of protoporphyrin
are not elevated in normal BALB/C mice, the BALB/C
recipient of the EPP skin graft showed no evidence of
photosensitivity either in the grafted EPP skin or in the sur-
rounding normal skin.
Discussion
The main pathological feature of EPP, skin photosensitivity,
which in some patients is severe, prevents them enjoying a
normal lifestyle including outdoors activities. In some cases
even exposure to artificial light causes symptoms (Kappas
et al, 1995). Moreover, a certain percentage of patients also
suffer from hepatic dysfunction, which in some cases leads
to terminal liver failure (Bloomer et al, 1996). Previous ex-
periments using the EPP mouse model has clearly shown
that the major source of excess protoporphyrin derives from
the erythroid compartment (Fontanellas et al, 2000) be-
cause of the extremely high level of porphyrin metabolism
occurring in these cells. Our results confirm this previous
observation. Transplant of bone marrow cells obtained from
EPP disease donor mice into irradiated, normal BALB/C
recipients resulted in a high level of reconstitution of the
hematopoietic system with cells of the donor EPP pheno-
type leading to greatly elevated levels of erythrocyte and
plasma protoporphyrin indistinguishable from control, non-
transplanted EPP disease mice. Moreover, FACS analysis of
red blood cells from BALB/C mice transplanted with EPP
marrow showed that most cells produced an abnormal,
protoporphyrin-specific fluorescent phenotype.
Interestingly, despite these greatly elevated levels of
erythrocyte and plasma protoporphyrin, BALB/C recipients
of EPP marrow showed no evidence of liver dysfunction as
assessed by monitoring serum levels of bilirubin, alkaline
phosphatase, and transaminases out to 16 mo post-trans-
plantation. Moreover, histopathologic examination of liver
sections from sacrificed animals showed no evidence of
biliary cirrhosis, regenerative hyperplasia, extracellular dep-
osition of protoporphyrin, abnormalities characteristically
observed in 100% of non-transplanted EPP disease mice.
Fontanellas et al (2000) has shown that transplantation of
normal congenic mouse bone marrow into very young re-
cipient EPP disease mice can prevent hepatobiliary com-
plications and partially reverse protoporphyrin accumulation
in the liver. Our results extend this earlier study by demon-
strating that high levels of blood protoporphyrin is in itself
insufficient to generate liver damage and that lack of fe-
rrochelatase activity in cells of the liver plays a critical role
in the development of the EPP-associated liver disease, at
least in the mouse model. In humans the situation remains
less clear. In a study of 112 EPP patients from 93 EPP
families, Minder et al (2002) found a significant association
between the possession of null-allele mutations that cause
major structural alterations in the ferrochelatase enzyme,
leading to the accumulation of especially high levels of pro-
toporphyrin in the blood, and protoporphyrin-related liver
disease in EPP. Moreover, in a follow-up study of seven EPP
patients who received a liver transplantation, two patients
had a recurrence of protoporphyric liver disease as as-
sessed by liver chemistries and histopathological analysis
of liver biopsies (Bloomer et al, 1996). The remaining five
patients all showed normal liver chemistries and liver biop-
sies (Bloomer et al, 1996). It is important, however, to note
that the two patients with recurrent liver disease following
liver transplantation also showed signs of liver rejection,
cytomegalovirus infection, and biliary tract obstruction that
may have played a role in the development of damage to
the transplanted liver (Bloomer et al, 1996). Conversely,
Chen et al (2002) concluded from a study of 34 EPP patients
from 24 EPP families that null mutations leading to high
levels of blood protoporphyrin levels could not, by them-
selves, account for the severe liver phenotype since the
same mutations were also observed in EPP patients not
suffering from liver disease at the time of the study. A pos-
sible explanation for these discordant observations is that
the patients with null mutations and greatly elevated levels
of blood protoporphyrin but no clinically detectable liver
disease were on their way to developing liver disease, but
Figure 4
BALB/C recipients of erythropoietic protoporphyria (EPP) marrow
show only very mild photosensitivity despite greatly elevated lev-
els of circulating protoporphyrin. At 3 mo post-transplantation mice
were shaved, depilated, and exposed to a mercury vapor lamp (5.52 J
per cm2 of 400–410 nm light) to mimic exposure to sunlight. Photo-
graphs were taken 5 d post-exposure. Non-transplanted (Non-Tx) nor-
mal BALB/C (A) and EPP (B) mice were used as controls. The bottom
panels show two BALB/C recipients transplanted with EPP marrow (C,
D). Note the very mild photosensitivity (small areas of mild ulceration)
as compared with the non-transplanted EPP mouse (large areas of
severe ulceration and crusting).
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insufficient time had passed for the disease to become
detectable. Alternatively, other genetic and/or acquired
factors may play a critical role in the development of
EPP-associated liver disease.
The most critical pathological feature of both murine and
human EPP is skin photosensitivity. We and others have
previously demonstrated that transplantation of either nor-
mal murine HSC or murine EPP HSC transduced with a
retroviral vector encoding the wild-type ferrochelatase
cDNA into EPP disease recipient mice can cure the skin
photosensitivity observed in murine EPP (Pawliuk et al,
1999; Fontanellas et al, 2000, 2001; Richard et al, 2001). In
all of these studies, the transplantation of wild-type or ge-
netically corrected EPP HSC resulted in a normalization of
blood protoporphyrin levels leading to long-term cure of
the photosensitive phenotype. Interestingly, in this study
we found that despite massive elevation in blood pro-
toporphyrin levels in BALB/C recipients of EPP donor mar-
row, photosensitivity was almost completely abrogated.
These results suggest that the expression of normal levels
of ferrochelatase enzyme in the skin is sufficient to metab-
olize the local circulating levels of protoporphyrin and pre-
vent photosensitivity. This conclusion is further supported
by the observation of a photoprotective effect within a re-
gion of normal skin following transplant onto the back of an
EPP disease mouse. This observation raises the interesting
possibility that as an alternative to HSC gene therapy, more
localized treatment of exposed regions of skin with a ther-
apeutic onco-retroviral or lentiviral vector might provide a
sufficient corrective effect to enable patients to engage in
outdoor activities. We are currently investigating the pho-
toprotective effect following lentiviral-mediated transfer of a
functional ferrochelatase cDNA to the dermal cells of EPP
mice. This localized treatment, however, would not have an
effect upon the high circulating levels of protoporphyrin
within the blood and would not, therefore, prevent the de-
velopment of liver damage.
This study has confirmed that the bone marrow is the
main source of excess protoporphyrin and has demonstrat-
ed that high circulating levels of protoporphyrin within the
blood is insufficient by itself to lead to the development of
the liver damage and the photosensitivity characteristic of
murine EPP. The development of methods to stably and
efficiently deliver a functional ferrochelatase enzyme locally
into the dermis of EPP mice should contribute to the de-
velopment of successful clinical protocols for the treatment
of human EPP.
Materials and Methods
Mice BALB/C-Fechm1Pas (hereafter referred to as EPP mice) and
BALB/C mice were purchased from The Jackson Laboratory (Bar
Harbor, Maine). Eight- to 12-wk-old female and male mice were
used, respectively, as donors and recipients. All experiments in-
volving animals were approved by the Massachusetts Institute of
Technology Committee on Animal Care.
Bone marrow transplantation Femoral bone marrow cells were
harvested from female EPP or BALB/C mice following sacrifice.
Cells were spun down, suspended in Hanks balanced salt solution
(Invitrogen, Carlsbad, California) containing 2% fetal bovine serum
(Hyclone, South Logan, Utah), counted and injected intravenously
into each male BALB/C mouse given 880 cGy of whole-body
irradiation (80 cGy per min 137Cs g-rays).
Erythrocyte protoporphyrin concentrations and skin photo-
sensitivity assay Erythrocyte protoporphyrin was measured as
previously described (Piomelli, 1977). The backs of mice were
shaved and depilated. An hour after depilation, the mice were
Figure 5
Normal levels of ferrochelatase expressed in the skin protects against photosensitivity. One month following skin transplantation the backs of
mice were shaved, depilated, and exposed to 20 min of a mercury vapor lamp. Areas of the skin graft are circled. The erythropoietic protoporphyria
(EPP) recipient of the BALB/C skin graft shows burns over a large area of the back. Note the lack of burns within the area of the normal skin graft.
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exposed to a mercury vapor lamp (Spectroline, model BIB-150B,
Spectronics Corp., Westbury, New York) that was filtered
with window glass to remove ultraviolet B radiation. The spectral
output of the filtered lamp was 320–580 nm and the dose of
400–410 nm radiation was 5.52 J per cm2. The mice were
observed daily for the development of skin lesions and photo-
graphed at 5 d post-irradiation. Control experiments demonstrated
that depilated non-porphyric BALB/C mice could be exposed to
1 h of mercury vapor lamp radiation and still not develop any
skin lesions.
Histopathology Livers were removed from mice following sacri-
fice and placed in 10% neutral buffered formalin (VWR, Batavia,
Illinois). Sections were prepared and stained with hematoxylin and
eosin. Analysis of sections was performed by a trained Veterinary
Pathologist.
Skin transplants Normal, BALB/C and diseased EPP mice were
anesthetized with 300 mL of 2.5% of freshly prepared Avertin. The
backs of the mice were shaved, depilated, and wiped with disin-
fectant. A circular patch of skin approximately 1.0 cm in diameter
was cut from the lumbar region of the dorsum of both BALB/C and
EPP disease mice with a scalpel blade. Next, the grafts were
switched so that they were placed onto the backs of recipient mice
of the opposite phenotype and the grafts were sutured into place
with 5-0 silk. Mice were bandaged, wrapped with cloth tape, and
monitored until fully recovered. Upon recovery, erythrocyte pro-
toporphyrin concentrations and skin photosensitivity was as-
sessed as described above.
Statistical analysis The Student t test was utilized to determine
statistical significance. p-values are indicated in the Results.
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